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Abbreviations:
Ce

cerium

CSF

cerebrospinal fluid

EELS

electron energy loss spectroscopy

ENM

engineered nanomaterial

ICP-MS

inductively coupled plasma mass spectrometry

MDL

method detection limit

PC

protein carbonyl

ROS

reactive oxygen species

TEM

transmission electron microscopy
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Abstract:
Background: Nanoceria is used as a catalyst in diesel fuel, as an abrasive in printed
circuit manufacture, and is being pursued as an anti-oxidant therapeutic. Objectives:
To extend previous findings showing that there were no reductions of cerium in organs
of the mononuclear phagocyte (reticuloendothelial) system up to 30 days after a single
nanoscale ceria administration. Methods: An ~ 5% aqueous dispersion of citratestabilized 30 nm ceria, synthesized and characterized in-house, or vehicle, was iv
infused into rats terminated 1, 7, 30 or 90 days later. Cage-side observations were
obtained daily; body weight weekly. Daily urinary and fecal cerium outputs were
quantified for 2 weeks. Nine organs were weighed and samples collected from 14
tissues/organs/systems, blood and cerebrospinal fluid for cerium determination.
Histology and oxidative stress were assessed. Results: Less than 1% of the nanoceria
was excreted in the first 2 weeks; 98% in feces. Body weight gain was initially impaired.
Spleen weight was significantly increased in some ceria-treated groups, associated with
abnormalities. Ceria was primarily retained in the spleen, liver and bone marrow. There
was little decrease of ceria in any tissue over the 90 days. Granulomas were observed
in the liver. Time-dependent oxidative stress changes were seen in the liver and spleen.
Conclusions: Nanoscale ceria was persistently retained by organs of the mononuclear
phagocyte system, associated with adverse changes. The results support concern
about the long-term fate and adverse effects of inert nanoscale metal oxides that
distribute throughout the body, are persistently retained, and produce adverse changes.
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Introduction:
Engineered nanomaterials (ENMs) have potential to contribute to applications that could
produce intended (e.g., drug and gene delivery) or unintended (e.g. occupational and
environmental) exposure. Understanding potential ENM toxicity lags behind application
development, as is usually the case for new technologies. Insufficient understanding of
ENM hazards could lead to human health problems and decreased public acceptance.

Ceria (cerium [Ce] oxide) ENMs have many current and potential commercial
applications. Ceria is highly insoluble, including in phagolysosomal fluid at pH 4.5 (He et
al., 2010) and abrasive, enabling its use in chemical-mechanical planarization
(integrated circuit manufacture) (Feng et al., 2006). Most ceria applications capitalize on
its redox activity, including as an oxygen sensor (Molin et al., 2008), diesel fuel catalyst
(increases combustion and converts carbon monoxide to carbon dioxide) (Cassee et al.,
2011; HEI, 2001; Park et al., 2007), in fuel cells (Yuan et al., 2009), and for potential
medical applications.

Therapeutic ceria ENM applications are generally based on its ability to reduce reactive
oxygen species (ROSs). Using many different cells in culture ceria, ENMs have been
shown to reduce levels of H2O2, the superoxide radical, i-NOS, NF-κB, TNF-α,
interleukins, and other ROS endpoints. It has been suggested that ceria ENMs have
utility in the prevention and/or treatment of cancer, diabetic cardiomyopathy, diesel
exhaust- and cigarette smoke-induced oxidative stress, radiation therapy side effects,
retinal degeneration, stroke, and neurodegenerative disorders (Babu et al., 2010; Chen
7

et al., 2006; Colon et al., 2010; D'Angelo et al., 2009; Das et al., 2007; Estevez et al.,
2011; Hirst et al., 2009; Niu et al., 2011; Xia et al., 2008; Younce et al., 2010). Ceriamediated ROS reduction may relate to its properties as a SOD mimetic and its catalaselike activity (Korsvik et al., 2007; Pirmohamed et al., 2010) and is perhaps attributed to
Ce(III) rather than Ce(IV) (Celardo et al., 2011). Most of these studies were conducted
in models of induced oxidative stress.

On the other hand, there are reports of ceria-induced toxicity, indicated by decreased
cell viability, glutathione, and DNA content; and increased LDH release,
malondialdehyde production, and apoptosis (Auffan et al., 2009; Brunner et al., 2006;
Lin et al., 2006; Park et al., 2008). Most of these studies were conducted in non-ROS
stimulated cells. The reported effects of ceria ENM on non-mammalian organisms have
generally been detrimental, including decreased growth, fertility, and survival; and
increased lipofuscin accumulation and susceptibility to oxidative stress, shown in
Pseudokirchneriella subcapitata (green algae), Synechocystis PCC6803 and Anabaena
CPB4337 (cyanobactreria), E. coli, Daphnia magna, and C. elegans (Rodea-Palomares
et al., 2011; Roh et al., 2010; Thill et al., 2006; Van Hoecke et al., 2009; Zeyons et
al., 2009; Zhang et al., 2010). These studies do not inform about the long-term effects
and fate of ceria ENM in the intact mammal, the target of medical applications and a
receptor of unintended exposures.
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Nanoscale ceria was identified for toxicity evaluation by the NIEHS ILS, 2006) and
OECD Environment Directorate (OECD, 2008). The need for in vivo studies that
examine its biokinetics and toxicity was recently identified (Cassee et al., 2011).

A few studies with ceria ENM have been conducted in the intact mammal. Reduced
myocardial oxidative stress was seen in transgenic mice that display ischemic
cardiomyopathy (Niu et al., 2007). Granulomatous inflammation was seen after
pulmonary instillation and inhalation (Cho et al., 2010; Srinivas et al., 2011). Intravitreal injection reduced retinal vascular lesions (Zhou et al., 2011).

Most therapeutic applications of ceria ENM will require systemic or pulmonary
administration as its oral absorption is poor (~0.001%), although somewhat better from
the lung (~0.1 to 1%) (He et al., 2010; Hirst et al., 2011; Yokel et al., submitted for
publication). Translocation can occur from the lung (and potentially other sites of
uptake) to blood and ultimately all organs (He et al., 2010). Therefore the fate of ceria
that is introduced into, or reaches, blood needs to be better understood.

Our previous research showed persistence in liver and spleen up to 30 days after
systematic introduction of 5, 15, 30, and 55 nm ceria ENMs (Yokel et al., submitted for
publication). Ceria increased the protein oxidation marker protein carbonyl (PC) levels in
liver 30 days after 5 nm ceria ENM treatment. Ceria-containing macrophages were seen
in the spleen and liver 30 days after 5 and 30 nm ceria ENMs, associated with hepatic
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granulomas comprised of Kupffer cell cores, surrounding mononucleated cells, and CD3
positive T lymphocytes (Tseng et al., submitted).

The present study was conducted to test the hypotheses that a significant amount of
ceria ENM persists in the mammal beyond 30 days and that adverse tissue changes
seen 30 days after ceria administration progress. The objectives were to ascertain the
distribution, translocation, elimination, and selected biological effects (including
histopathology and oxidative stress) for 90 days after a single iv ceria ENM infusion.
The iv route was selected to model the ceria that would enter systemic circulation after
translocation from any uptake site, such as the lung, as well as its iv administration, as
might be employed when used as a therapeutic agent.
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Materials and Methods
Nanomaterial:
A ~5% aqueous citrate-stabilized ceria dispersion was synthesized using a
hydrothermal approach (Mai et al., 2005). It was citrate coated (capped) to prevent the
agglomeration seen with uncoated ceria that occurs in high ionic strength solutions,
such as blood (Xia et al., 2008). Citrate is a commonly used surface coating agent for
ENMs, a component of blood (~ 100 µM in humans), and has been shown to have no
effect on erythrocyte response to a silver ENM (Choi et al., 2011). Generally, a 20 ml
aqueous mixture of 1 mmol cerium nitrate and 105 mmol sodium hydroxide were stirred
for 0.5 h. This produced a milky suspension that was transferred into a Teflon-lined
stainless steel bomb and heated at 180 °C for 24 h. The fresh white precipitate was
then washed with deionized water three times followed by ethanol three times to
remove free cerium and organic impurities. The wet precipitate was then dispersed into
0.05 M citric acid aqueous solution with stirring overnight, followed by washing with
water 5 times. The resulting dispersion had a pH of 3.9. It was sterilized by autoclaving.
To determine whether autoclaving affected the ceria ENM concentration, quadruplicate
samples of the dosing material were prepared for Ce analysis before and after
autoclaving. Eleven samples of the dosing material were digested by 2 methods and
analyzed by inductively coupled plasma mass spectrometry (ICP-MS) to quantify ceria
content (Yokel et al., 2009). It was 5.2 ± 0.1%. Based on the volumes infused the dose
given the rats was ~ 87 mg ceria/kg. The autoclaved ceria ENM was iv infused without
any further treatment.
11

Ceria characterization:
The morphology, crystallinity, and particle size distribution of highly diluted samples of
the citrate-coated ceria ENM were determined in our laboratories using high resolutiontransmission electron microscopy (TEM)/scanning transmission electron microscopy
and X–ray diffraction analyses/scanning TEM (200-keV field emission analytical
transmission electron microscope [JEOL JEM-2010F, Tokyo, Japan] equipped with an
Oxford energy dispersive X-ray spectrometer). The primary particle size was
determined using Gatan software (DigitalMicrograph 3.7.1, Pleasanton, CA) by sizing
110 particles. From the data of individual primary particle sizes measured from the TEM
images, a number frequency cumulative distribution was constructed. The cumulative
distribution was best described by a log-normal distribution model, characterized by a
sample mean and a standard deviation. The data were well-described by a mono-modal
distribution, e.g., one continuous distribution was observed with no significant
secondary or tertiary peaks. The reported ‘average’ diameter of each sample
was Dave = exp(µ ) , where µ is the mean of the log-normal probability distribution, and the
reported ‘standard deviation (SD)’ is the value from the fit of the log-normal distribution
to the data. A number-based differential frequency distribution was constructed using
the model coefficients. The ceria nanoparticles were crystalline and highly pure as
determined by X–ray diffraction (Siemens 5000 diffractometer). Particle size distribution
in aqueous dispersion was determined using dynamic light scattering (90Plus
Nanoparticle Size Distribution Analyzer, Brookhaven Instruments Corp, Holtsville, NY).
12

The surface area of the dried powder was determined by isothermal nitrogen adsorption
using a BET surface area analyzer (Tristar 3000; Micromeritics Instrument Corporation,
Norcross, GA, USA). To indicate the stability of the ceria dispersion when infused into
the rat, the zeta potential was measured using a Zetasizer nano ZS (Malvern
Instruments, Worchestershire, UK). Since the ceria ENM had a hydrodynamic diameter
< 200 nm, the Hückel approximation was used to calculate zeta potential from
electrophoretic mobility. STEM images were acquired using the high resolution probe at
2 Angstrom in a 2010F STEM outfitted with a URP pole piece, GATAN 2000 GIF,
GATAN DigiScan II and EmiSpec EsVison software. The ceria ENM was analyzed prior
to administration using electron energy loss spectroscopy (EELS) to determine its
M4/M5 ratio as a measure of its original oxidative signature. EELS measurements
were performed using the 0.2 Angstrom probe, an alpha of 20 mrad, and a beta of 6
mrad to estimate the Ce(III) vs. Ce(IV) oxidation states from the M4/M5 ratio,
respectively. The interior of the 30 nm ceria ENM and the exterior particle surface were
separately analyzed. To estimate the extent of citrate surface coating the ceria ENM
was washed at least three times with water before drying. Thermogravimetric analysis
(Perkin-Elmer TGA7 Analyzer) was then performed to determine the weight loss of the
citrate-coated ceria ENM from 150 to 300°C over which decomposition of citric acid
occurs. The extent of citrate surface coating was estimated based on the assumption
that the ceria ENM was spherical and had a uniform size. The free Ce concentration in
the washed ceria ENM dispersion was determined using Amicon Ultra-4 centrifugal
3000 molecular weight cut-off filter devices and centrifugation at 3000 g to obtain filtrate,
which was analyzed by ICP-MS.
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Animals:
The results of this study are from 31 male Sprague Dawley rats, weighing 300 ± 19 g
(mean ± SD), purchased from Harlan, They were housed individually prior to study and
after cannulae removal (a few days after the iv infusion) in the University of Kentucky
Division of Laboratory Animal Resources facility under a 12:12 h light:dark cycle at 70 ±
8°C and 30 to 70% humidity. The rats had ad lib access to 2018 Harlan diet and RO
water. Animal work was approved by the University of Kentucky Institutional Animal
Care and Use Committee. The research was conducted in accordance with the Guiding
Principles in the Use of Animals in Toxicology.

Ceria administration:
In initial studies, un-anesthetized rats were infused iv with ~100 mg ceria ENM
dispersion/kg using described procedures (Yokel et al., 2009). Rats tolerated the ceria
infusion well. Therefore the test doses were ~100 mg ceria/kg (found by analysis to be
87 mg ceria/kg, equivalent to 70 mg Ce/kg) infused over 1 h, or water (controls for ceria
vehicle) adjusted to pH 3.9, infused over 1 h. This large ceria ENM exposure was
utilized to enhance our ability to detect Ce in multiple tissues and fluids up to 90 days
after the single infusion. Fifteen rats were infused with vehicle and 16 with ceria. Three
control and 3 ceria treated rats were terminated 1, 7, or 30 days after completion of the
infusion. Six control and 7 ceria treated rats were terminated 90 days after the infusion.
All rats were cage-side observed daily to assess respiratory, musculo-nervous,
ophthalmic and other abnormalities (the presence of dyspnea, tachypnea, tremor,
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ataxia, head tilt, hyperactivity, hypoactivity, lethargy, paralysis, opacity of the eyes,
dilated/constricted pupils, exophthalmia, enophthalmia, conjunctivitis, abnormal
secretions/crusting of the eyes, corneal ulcers, diarrhea, ruffled fur, urine staining, and
other notable observations). Each was weighed weekly. Rats scheduled for termination
at 7, 30, or 90 days were housed in metabolic cages from 3 days before until the 7th or
14th day after infusion. Urine and feces were collected daily from 6 control and 8 ceria
ENM-treated rats to 7 days and 6 control and 5 ceria ENM-treated rats to 14 days.

Ceria distribution and elimination:
Daily urine volume was determined. Daily feces weight was determined as the wet
feces and after drying to constant weight. At termination the brain, lung, thymus, heart,
spleen, liver, adrenal, right kidney, and right testis were rapidly removed and weighed.
Samples were obtained for Ce analysis from brain cortex, lung, thymus, heart
(horizontal medial cross-section), spleen (medial tip), liver (near tip of the larger of the
two bifurcated lobes), adrenal, right kidney (medial cross-section), intestine (a 1 cm
segment 5 to 6 cm below the pyloric sphincter), testis (internal issue), skeletal muscle
from the right femur, skin (from the middle of the back), bone marrow (tibia), whole
blood (vena cava), and cerebrospinal fluid (withdrawn from the cisternomedullary
space). The skeletal system was cleaned by Dermestidea beetles, cleaned of beetle
residue by placing the skeleton in deionized water in a Ziploc® bag which was sonicated
in a bath sonicator for 15 minutes, washed with deionized water, dried, and weighed.

15

Samples of each collected tissue and fluid, and skeletal system samples from the
cranium, spinal column, ileac crest (pelvis), and femur (representative of the
appendages) and the rat chow consumed by these subjects, were prepared and
analyzed for Ce by ICP-MS; Agilent 7500cx, Santa Clara, CA, USA) as previously
described, which reported the method detection limit (MDL) of Ce in tissue of 0.089 mg
Ce/kg and 0.018 mg Ce/l in blood or serum samples (Yokel et al., 2009). The
procedures to prepare and analyze the samples are described in the Supplemental
Information. Cerium concentrations below the MDL were reported as 50% of the
MDL. Organ/system Ce concentration in all tissues/fluids as well as mass amount of Ce
and percent of the ceria dose in the rat were calculated; the latter from the organ weight
or based on 0.02, 1.8, 50, 20, 3 and 7% of the body weight for the adrenal gland,
intestine, skeletal muscle, skin, bone marrow, and blood, respectively. The skeletal
system was separated into 4 components (cranium, spinal column, pelvis, and femur)
which constituted 21, 38, 10, and 31% of its weight, respectively.

Tissue preparation and histological evaluation: After termination of ketamineanesthetized rats harvested tissue samples were immediately immersed in 10% neutral
buffered formalin and subsequently processed by paraffin embedding for histopathology
analysis. Sections (5 µm) were cut and stained with hematoxylin and eosin and
examined for qualitative and quantitative changes. For plastic embedding, tissues were
cut into 3 mm3 pieces, post fixed in osmium tetraoxide, dehydrated, and embedded in
Araldite 502. One micron sections were cut and stained with toluidine blue. All sections
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were coded and examined by an experienced histologist and an experimental
pathologist.

Oxidative stress assessment:
Protein carbonyl (PC) levels, as a global marker for protein oxidation and oxidative
stress, were measured in liver and spleen using a specific antibody and slot blot
technique as described (Butterfield, 1997; Sultana et al., 2005). The liver and spleen
were examined because they had the highest ceria concentrations.

Data and statistical analysis:
Grubb’s test was used to identify outliers in fluid, tissue, urine and feces Ce results. A
two-way ANOVA was used to compare body weights of rats terminated 90 days after
treatment, normalized to their treatment day weight. Organ weights, not and normalized
to body weight, were compared by one way ANOVAs followed by Tukey’s multiple
comparison tests, and unpaired t tests. The percentage of the ceria dose in the liver,
spleen, kidney, heart, lung, brain, thymus, and testis was calculated based on each rat’s
whole organ weight times its Ce concentration, correcting for Ce as a percentage of
ceria. Median pre-treatment 24 h urine and feces Ce excretion obtained from 24 rats
was subtracted from post-treatment values of ceria-treated rats to obtain the excretion
of Ce attributable to treatments. The concentration of Ce and percent of dose in all
sampled tissues and fluids and of the four skeletal system regions were compared by
two way ANOVAs and Bonferroni multiple comparisons. One-way ANOVAs with Tukey
tests were also conducted to determine differences in the percent of dose across time in
17

each sampled tissue or fluid and across tissues and fluids at the same time. Results are
reported as mean ± SD, except for the PC levels in ceria-treated rats which were
normalized to their respective control samples and expressed as % mean ± SEM.
Significance was accepted at p < 0.05.
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Results:
Nanomaterial:
HR-TEM/HR-STEM showed the ceria ENM was crystalline (its only known structure is
face-centered cubic) (Figure 1A). It had Miller indices of (111), (220), and (311), and
with lesser presence of (200), (222), and (400), based on XRD crystal structure linked to
known morphology. Its average (and SD) primary particle diameter was 31.2 (17.1) nm.
The particle size distribution was bimodal. The peaks were centered at 41 and 273 nm;
the percentages of each peak were 100:0 (number basis) and 36:64 (volume basis).
Figure 1B shows the fit of the lognormal model (continuous curve) to the cumulative
distribution (number frequency basis). Figure 1C shows the differential distribution
computed from the model coefficients. Note that, for a log-normal distribution, the
mean of the distribution, μ, is not the peak of the differential distribution, but is displaced
to a slightly higher diameter. Primary ENM particles can agglomerate (self-associate) in
aqueous dispersions, yielding particles that tend to associate with each other rather
than the TEM grid (Figure 1A). Different weighting factors that can be used to estimate
average ENM size, including number-based (typically the result of TEM diameter
measurements), volume-based (which is dose-related as it links directly to the mass of
ENM of a specific size), and intensity (the signal from the light scattering experiment).
The bimodal distribution demonstrates that agglomeration occurred for this ENM. The
BET-determined surface area was 15 m2/gm, which would correspond to an average
diameter of 52 nm. The estimated differences between the TEM and BET methods
suggest that this ENM may self-associate with one whole face to form agglomerates,
reducing its apparent surface area. Some face-to-face agglomerates can be seen in
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Figure 1A. The zeta potential in water at pH ~ 7.3 was -56 (± 8) mV. The EELS results
show that the surface of the ENM had a slightly reduced valency at its outer rim and a
more enhanced valency (less reduction) in the central (core) region. This was observed
as a change in the height of the sharp intense peaks at the cerium M5 and M4 edges (~
883 and 900 eV). A representative EELS line scan from the exterior surface towards
the inner zone of the ceria shows the enrichment of Ce(III) at the particle rim (surface
layer) (Figure 1D). The extent of surface citrate coating was ~18%. The free Ce content
was << 1%. Cerium concentration after autoclaving was 99.1% of that seen prior to
autoclaving.

Animal observations:
All ceria-treated rats survived for their assigned study duration. Daily cage-side
observations revealed no adverse effects. There was no significant difference in daily
wet feces outputs during the first week between ceria-treated and control rats. The only
significant differences in urine outputs were greater output on day 3 among the ceriatreated rats terminated at 1 week compared to many of the other groups and a lower
output on day 4 compared to some groups. Ceria ENM-treated rats showed a reduced
body weight gain shortly after ceria administration (Figure 2). ANOVA results showed
significant effects of treatment and time but not a significant interaction. The spleen of
many ceria-treated rats showed punctate white specs. The only organ showing a
significant difference in weight between control and treated rats was the spleen. This
was not revealed by the one way ANOVA (P = 0.108), however 2-tailed unpaired t-tests
showed the treated rats to have significantly heavier spleens at 1 and 30 days (non- and
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normalized to body weight) and significantly lighter at 7 days (not normalized to body
weight) (Figure 3).

Ceria distribution and elimination:
Grubb’s test revealed 6 outlier Ce concentration results, among 304 tissue/fluid x
termination time x treatment conditions for the ceria ENM-treated rats. Among the 283
tissue/fluid samples from the control rats, 231 were below the MDL, vs. 19 of the 304
from treated rats, which were mainly brain (all 3 at 1 week and 1 month and 3 at 3
months) and CSF (2 at 1 day and 2 at 1 week).

Baseline (pre-ceria ENM treatment) 24 h urinary and fecal Ce excretion medians were
0.038 and 1.04 μg, respectively. One post Ce treatment feces value was on outlier.
When pre-treatment 24 h median Ce excretion was subtracted from total Ce excretion
post ceria ENM dosing, ~ 2 and 100 μg of ceria appeared in the urine and feces in the
first 2 weeks, representing ~ 0.01 and 0.5% of the dose, respectively (Figure 4).

Tissue/fluid Ce concentration results are shown in Figure 5A and expressed as a
percentage of the ceria dose in Figure 5B. Brain cerium concentration, corrected for the
cerium in the blood vessels of the brain, in concert with extensive light and electron
microscopic observations, suggested very little ceria ENM crossed the blood-brain
barrier into brain cells. A 2-way ANOVA of Ce concentration across time and among
sampled tissues and fluids F(3,14,42) = 2.9, 25.9 and 2.24 showed significant effects of
time, site and interaction (P = 0.036, < 0.0001, and = 0.0001, respectively). Bonferroni
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comparisons only showed a significant decrease of Ce in spleen from day 1 compared
to days 7 and 30 followed by a significant increase from days 7 and 30 compared to day
90. A 2-way ANOVA of the percent of the dose across time and among sampled tissues
and fluids F(3,14,42) = 4.06, 56.2 and 2.48 showed significant effects of time, site and
interaction (P = 0.008, < 0.0001, and < 0.0001 respectively). Bonferroni comparisons
only showed reductions in the percent of the dose in liver and bone marrow over time
and an increase in the spleen, but no differences among the sampled sites. The lack of
other significant differences might be due to the large number of comparisons in this
analysis. Therefore, one-way ANOVAs with Tukey tests of the percent of the dose in
each sampled site over time were conduced. They revealed significant reductions in the
heart (from day 1 to days 7, 30 and 90) and the brain (from day 1 to day 90). When all
sample sites were compared at a single time (1, 7, 30 or 90 days), liver was higher than
all sites but bone marrow, and bone marrow was higher than all other sites at day1; liver
and bone marrow were higher than all other sites at day 7; liver was higher than all sites
except bone marrow at day 30; and liver was higher than all sites but spleen, spleen
was higher than all sites but bone marrow, and bone marrow was higher than all other
sites but blood at day 90. These results show little decrease of Ce in the sampled sites
over time, much more ceria in the liver, bone marrow and spleen than other sites, and
evidence to translocation to the spleen at day 90. Figure 6 shows the ceria in the 4
skeletal system regions studied. Two-way ANOVAs showed significant effects of time
and region for Ce concentration and percent of dose but not interaction (F(3,3,9), =
3.82, 5.82, and 0.98 (P = 0.0157, 0.0018 and 0.47, respectively). The significant
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differences are shown in Figure 6. The spinal column and pelvis had considerably more
Ce than the femur and cranium.

The mean rat chow Ce concentration was 0.22 mg Ce/kg. Given that Sprague Dawley
rats eat ~ 5 g food/100 gm body weight daily
(http://www.aceanimals.com/SpragueDawley.htms), the daily Ce intake from food of
these rats would be ~ 4.4 μg, and over 90 days 0.3 mg, or less than 2% of the Ce in the
87 mg ceria/kg iv dose. Cerium is poorly absorbed from the GI tract (Durbin et al., 1956;
Gehlhaus et al., 2009; Miller and Byrne, 1970), as is ceria ENM (He et al., 2010; Hirst
et al., 2011; Park et al., 2009). Therefore, Ce in the rat chow did not significantly
contribute to blood and tissue Ce levels.

Liver, spleen, and bone marrow showed the most avid uptake and retention of ceria
ENM. The ceria-containing Kupffer cells situated in the sinusoids became visible by light
microscopy 1 day after infusion. Less visible was hepatocellular accumulation. The
continued presence of ceria after the single vascular infusion was associated with
hepatic granuloma formation first seen after 30 days that persisted in the 90 day
samples in all ceria-infused rats. These intra-sinusoidal cellular agglomerates
comprised a core of Kupffer cells surrounded by mononucleated cells. In spite of the
granulomatous formation, hepatic parenchyma remained viable (Figure 7A). Occasional
perivascular accumulation of lymphocytes was also observed and one T cell population
in the granuloma was identified by CD3 immunohistochemistry. In the enlarged spleen,
histological examination showed ceria-containing macrophages both in the red and
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white pulp in 30 and 90 day samples (Figure 7B). In the brain, unlike systemic tissue
rich in mononuclear phagocyte cells, light microscopy did not reveal cells with ceria
accumulation in neurites or the microvessels in the hippocampus (Figure 7C) or the
cerebellum (Figure 7D).

Oxidative stress assessment:
Protein carbonyl levels were increased significantly in liver 1, 7, and up to 30 d and later
decreased significantly 90 days after ceria treatment (Figure 8A). On the other hand, PC
levels were decreased significantly 1, 7, and 90 days after ceria treatment in spleen
(Figure 8B).
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Discussion:
The present study utilized an established 90 day toxicity protocol (1, 7, 30, and 90 days)
to study the short and longer term effects of a single dose of a nanoscale ENM, as was
employed to study the effects of intratracheal nanoscale quartz instillation (Warheit et
al., 2008). The study used an in-house synthesized 30 nm cubic ceria that was well
characterized, as required by this journal and advised by many (Bouwmeester et al.,
2011; Maynard et al., 2011; Powers et al., 2009; Sayes and Warheit, 2009).

The present study extends prior work that showed persistence of nanoscale ceria in
mice and rats for up to 7 and 14 days after its oral administration, 7 days after the last ip
injection, 28 days after its intratracheal instillation, and 30 days after its systemic
introduction (He et al., 2010; Hirst et al., 2011; Park et al., 2009; Park et al., 2010;
Yokel et al., submitted for publication). The present study extended the determination of
ceria in the rat up to 90 days and determined ceria in several more tissues and fluids
than previously reported (bone marrow, which is a major site of ceria ENM distribution,
and adrenal, thymus, skin and cerebrospinal fluid), providing a more complete
assessment of its fate. The use of a large ceria ENM dose enabled us to see cerium in
all sampled tissues and fluids up to 90 days, in comparison to prior work, some of which
employed lower doses. Additionally, this study employed both ICP-MS and electron
microscopy to determine ceria distribution, providing insight into the subcellular
localization of the ceria. By determining multiple endpoints in one study, namely ceria
disposition and persistence, subcellular localization in selected tissues, safety as cageside observations, effects assessment including protein carbonyls as a major indicator
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of oxidative stress and histological evaluation, and determination of the valence of
nanoceria in vivo which has not been previously reported by anyone, this study enabled
the interpretation of the temporal inter-relationship of these endpoints.

The short-term reduction of body weight gain compared to controls has been previously
observed after high dose intratracheal instillation of ceria ENM (~ 130 nm ceria given to
mice (Park et al., 2010). Given the large dose of ceria ENM, body weight gain reduction
is not unexpected. The lack of morbidity (observable clinical toxicity) and mortality over
the 90 days shows this dose of the studied ceria ENM did not produce profound toxicity,
although abnormal changes were observed in the liver and spleen, discussed below.
Splenomegaly after ENM exposure was reported after iv administration of a 49 nm
magnetite-dextran ENM (Okon et al., 2000), and seen 30 days after a single iv
administration of 5, 15, and the same 30 nm ceria ENM (Yokel et al., submitted for
publication). The cause of this finding will require further study.

The very small clearance of ceria, nearly all into feces, during the first 2 weeks after
ceria ENM administration has been previously noted, although the prior studies did not
quantify urinary cerium excretion after oral, intratracheal, iv, or ip ceria ENM
administration (He et al., 2010; Hirst et al., 2011). Given the ceria ENM was not
eliminated to any significant extent, its prolonged retention is not surprising. Ceria, as
Ce, was detectible in all tissues and fluids sampled at 90 days. There was no
appreciable clearance of the ceria ENM over the 90 days, which was mostly present as
intracellular ceria agglomerations in mononuclear phagocyte system tissues. Of the
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64% of the ceria ENM dose found in the sampled organs and fluid compartments 90
days after its administration, 72% was in the liver, spleen and bone marrow. This is
consistent with the accumulation of other insoluble metal and metal oxide ENMs in the
liver, spleen, and bone marrow, e.g. (Ballou et al., 2004; Choi et al., 2007; Fabian et
al., 2008; Moghimi et al., 2001). Given the lack of ceria ENM clearance, it is assumed
that a single large ceria ENM dose would model tissue cerium levels after repeated,
smaller, doses. We have found that the percentage of the dose of a 5 nm ceria ENM in
the liver is comparable after a single iv administration of 11 mg ceria/kg, 5
administrations of this dose given over consecutive days, and a single administration of
56 mg ceria/kg (unpublished results).

Prior studies found granulomas in the lung 7 days and in lymphocytes 14 days after ~
130 nm ceria given intratracheally to mice (Park et al., 2010). Multifocal
microgranulomas changes were seen in the lung by day 14 of daily head-and-nose-only
inhalation of 15 to 30 nm ceria ENM and granulomatous changes were observed in the
lung 28 days after ceria ENM instillation into lungs of rats (Cho et al., 2010; Srinivas et
al., 2011). Other than the observation of granulomas in a few rats that received the
lowest of the 3 doses of silver ENM by inhalation (Sung et al., 2009), the current study
seems to be the first report of granulomatous changes in the mammalian liver after
metal or metal oxide ENM administration. No progression or diminution of the
granulomatous changes in the liver was seen over the 90 days. The long term fate and
effect of this inflammatory reaction is unknown.
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One of the mechanisms by which nanomaterials interact with biological systems is by
generation of free radicals (Nel et al., 2006). Depending on the reactivity and half life of
free radicals, they can interact with and damage proteins, lipids, and nucleic acids.
Apart from other important cellular functions, proteins can function as antioxidant
enzymes or molecules, which comprise the cellular defense against free radicalmediated oxidative stress. The interaction between proteins and free radicals may
change the 3D structure of proteins by oxidative modification of the protein backbone or
amino acid residues (Stadtman, 2006). A change in its 3D structure may affect or inhibit
protein functions. The extent of oxidative damage of a protein can be estimated by PC
levels, a global marker for protein oxidation. Therefore, PC levels were measured in
control and ceria-treated rat liver and spleen samples. Increased PC levels in liver were
found at most time points examined. These results confirmed earlier findings on liver PC
at 30 days following a single iv 5 nm ceria ENM infusion (Tseng et al., submitted). There
are few in vitro and in vivo studies reporting hepatotoxicity of nanomaterials which also
reported pro-oxidant effects of ENM treatment (Hussain et al., 2005; Loh et al., 2010;
Patlolla et al., 2011; Sayes et al., 2005; Yuan et al., 2011). Although many studies
reported ENM accumulation in the spleen (Ballou et al., 2004; Choi et al., 2007; Fabian
et al., 2008; Moghimi et al., 2001), oxidative stress effects of ENM treatment were not
investigated. A recent study reported no effect on inflammatory cytokine release from
spleen microphages after magnetic Fe2O3 ENM treatment (Wang et al., 2011). In
contrast to liver, PC levels were decreased in the spleen at each time point examined
(but statistical significance for the results at 30 days was not reached). This difference
in response from liver and spleen cells to ceria ENM treatment may be due to
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differences in the cellular types in these organs. Interestingly, after 90 days ceria ENM
induced anti-oxidant effects in both organs. Consequently, our findings suggest that
there is a time-dependence to the effects of ceria treatment with respect to peripheral
organs. These effects may relate to the oxidation state of the ceria ENM (Celardo et al.,
2011; Korsvik et al., 2007; Pirmohamed et al., 2010), which we found to be enriched
with Ce(III) at the particle surface in this study. As there is a very limited literature
available on short term and long term effects of ENM treatments, it is difficult to discuss
the variation in the oxidative stress response within an organ or from organ to organ.
Therefore, short and long term effects of ENM treatment on redox status of liver and
spleen are under investigation.

Ceria is considered an inert material, from a solubility standpoint. However, due to its
redox catalytic properties, it has significant chemical activities, for which it is used and
being pursued in many applications, as noted in the Introduction. Its lack of solubility
probably contributes to its persistence and its catalytic activity probably contributes to its
effects on oxidative stress endpoints. It is unclear if the adverse effects seen in the liver
and spleen are due to mechanical irritation from its presence or its chemical (catalytic)
activity. These results further support the concern about inert nanoscale metal oxides
that are introduced into, or reach, systemic circulation, from which they can distribute
throughout the body, and result in persistent retention and potential adverse effects in
multiple organs.
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The present results provide information assessing the health effects of nanoceria.
Although much was learned about the distribution and retention of ceria ENM and
concurrent effects, there are limitations to this, and any, study. One is the use of a
laboratory-generated ENM for study, which might not be representative of commercial
nanoceria. Indeed, our initial study utilized a commercial ceria ENM; however we were
unable to obtain from the supplier some characterization information needed to fully
understand the ENM (Yokel et al., 2009). This led to our decision to manufacture and
characterize in house our ENM study materials, enabling us to better understand the
material we are studying. As noted in the Introduction, nanoceria is utilized in multiple
applications. These would represent different physicochemical forms, with different
surface capping agents, and in different dispersing media, or as solids. It is not
feasible, time-wise or economically, to characterize well all nanomaterials (Choi et al.,
2009), making it necessary to extrapolate or use other approaches such as tiered
testing systems and grouping (banding) similar ENMs. For this study we selected a
ceria ENM size that appears to be in the range where ENMs are most different from the
effects of their solution or bulk scale components, based on protein binding (Nel et al.,
2009), cell uptake (Chithrani et al., 2006), and induction of acellular oxidative stress
(Jiang et al., 2008). It is anticipated that ceria ENM solubility would not be influenced by
size, which relates to persistence, a major focus of this study. We must also realize that
ENMs are highly reactive and therefore their composition can change in the body of the
organism exposed to them, e.g. by opsonization, and in the environment. It is important
to begin investigations on the kinetics and effects of nanomaterials of known
composition. The present results add to prior knowledge about ceria ENMs and identify
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some of the issues that warrant further study to more fully characterize their health
effects.

Conclusions: A single ceria ENM administration initially reduced body weight gain.
Cerium excretion following ceria ENM infusion was 98% in the feces and very slow,
resulting in elimination of < 1% of the dose in the first two weeks. Spleen weight was
greater at most times after ceria ENM administration, associated with visual and
microscopic evidence of abnormality. Nanoscale ceria was retained in mononuclear
phagocyte system tissues from which there was little clearance over 90 days,
supporting the hypothesis that a significant amount of ceria ENM persists in the
mammal well beyond 30 days. However, the lack of morbidity, mortality or significant
progression (or regression) of adverse changes in the liver and spleen fail to support the
hypothesis of progression of untoward effects beyond 30 days. The long term effects of
nanoscale ceria that enters cells warrants investigation, considering the near
irreversibility of its accumulation.
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Figure legends.
Figure 1. Panel A: TEM image of 30 nm ceria showing cubic particles. The insert in the
top right hand corner is an electron diffraction pattern verifying the ceria crystallinity.
Panels B and C: Primary particle size distribution of the ceria ENM, as determined by
TEM, showing cumulative and differential frequency distributions. Panel B shows the
TEM size distribution data as points and a lognormal model as a continuous curve.
Panel C shows the differential distribution as represented by the lognormal model.
Panel D: HR-STEM image of the as-produced ceria ENM. EELS analyses were
conducted along the indicated trace line (arrow) starting at the exterior rim or surface
layer and ending in the core region. The computed M4/M5 ratio shows the change in the
oxidation state.

Figure 2. Body weight of control and ENM-ceria treated rats after treatment.

Figure 3. Spleen weight, as a percent of body weight. * = significantly different from
control at same time by t-test.

Figure 4. Daily urine (A) and fecal (B) Ce excretion of 5 ceria-treated rats, as mass
amount (left panels) and as a percentage of the dose (right panels). Note the 50-fold
difference in the Y axis scales between urine and feces.
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Figure 5. Cerium concentration (A) and percent of the dose (B) in tissues, blood and
cerebrospinal fluid (CSF). Skeletal system Ce concentration is the mean of the 4
regions and % of dose is the sum.

Figure 6. Cerium concentration (A) and percent of the dose (B) in the 4 skeletal system
regions. Significantly different, p < 0.05, 0.01, 0.001 and 0.0001, *, **, *** and ****,
respectively.

Figure 7. Histology of liver, spleen, hippocampus, and cerebellum 90 days after ceria
ENM infusion. Panel A shows the normal appearing liver with a granuloma formation.
Panel B was taken from the white pulp of a spleen showing phagocytic cells with ceria
particulates. Panel C illustrates a CA1 pyramidal cell and adjacent small vessel (arrow),
both free of ceria. Panel D shows cerebellar tissue and the absence of ceria in both the
neuronal and vascular components (arrow).

Figure 8: Panel A histogram represents protein carbonyl levels in liver 1 day, 7 days, 30
days and 90 days after ceria treatment measured in control and ceria treated rats.
Significant difference reported for **p< 0.01 and ***p< 0.001. Panel B histogram
represents protein carbonyl levels in spleen, 1 day, 7 days, 30 days and 90 days after
ceria treatment measured in control and ceria treated rats. Significant difference
reported for *p< 0.05, and **p< 0.01.
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